Small molecules that reactivate mutant p53.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  European Journal of Cancer

• Publication date

  2003-09-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/S0959-8049(03)00454-4PMID 12932659
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Activation of p53 by the cytoprotective aminothiol WR1065: DNA-damage-independent pathway and redox-dependent modulation of p53 DNA-binding activity.

  2003cited by this paper
• The Cytoprotective Aminothiol WR1065 Activates p53 through a Non-genotoxic Signaling Pathway Involving c-Jun N-terminal Kinase*

  2003cited by this paper
• Stabilization of p53 by CP-31398 Inhibits Ubiquitination without Altering Phosphorylation at Serine 15 or 20 or MDM2 Binding

  2003cited by this paper
• Protein Folding and Disease: a view from the first Horizon Symposium

  2003cited by this paper
• Glycerol as a chemical chaperone enhances radiation-induced apoptosis in anaplastic thyroid carcinoma cells

  2002cited by this paper
• A peptide that binds and stabilizes p53 core domain: Chaperone strategy for rescue of oncogenic mutants

  2002cited by this paper
• Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database.

  2002cited by this paper
• The p53-stabilizing compound CP-31398 enhances ultraviolet-B-induced apoptosis in a human melanoma cell line MMRU.

  2002cited by this paper
• Characterization of the p53-rescue drug CP-31398 in vitro and in living cells

  2002cited by this paper
• Restoration of wild‐type conformation and activity of a temperature‐sensitive mutant of p53 (p53V272M) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE‐1

  2002cited by this paper
• Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound

  2002cited by this paper
• The p53 stabilizing compound CP-31398 induces apoptosis by activating the intrinsic Bax/mitochondrial/caspase-9 pathway.

  2002cited by this paper
• The Mutant p53-Conformation Modifying Drug, CP-31398, Can Induce Apoptosis

  2002influential reference
• Rescuing the function of mutant p53

  2001cited by this paper
• ASPP proteins specifically stimulate the apoptotic function of p53.

  2001cited by this paper
• Understanding protein folding via free-energy surfaces from theory and experiment.

  2000cited by this paper
• Surfing the p53 network

  2000cited by this paper
• Mutant p53 mediated induction of cell cycle arrest and apoptosis at G1 phase by 9-hydroxyellipticine.

  1999cited by this paper
• Restoration by glycerol of p53-dependent apoptosis in cells bearing the mutant p53 gene.

  1999cited by this paper
• Pharmacological rescue of mutant p53 conformation and function.

  1999cited by this paper
• Reactivation of Mutant p53 through Interaction of a C-Terminal Peptide with the Core Domain

  1999cited by this paper
• Mining the National Cancer Institute Anticancer Drug Discovery Database: cluster analysis of ellipticine analogs with p53-inverse and central nervous system-selective patterns of activity.

  1998cited by this paper
• Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain

  1997cited by this paper
• An Information-Intensive Approach to the Molecular Pharmacology of Cancer

  1997cited by this paper
• Structure of the p53 Tumor Suppressor Bound to the Ankyrin and SH3 Domains of 53BP2

  1996cited by this paper
• Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.

  1994cited by this paper
• Solubility as a Function of Protein Structure and Solvent Components

  1990cited by this paper

• RELA Ablation Contributes to Progression of Hepatocellular Carcinoma with TP53R249S Mutation and is a Potential Therapeutic Target

  2025cites this paper
• High p53 Protein Level Is a Negative Prognostic Marker for Pancreatic Adenocarcinoma

  2024cites this paper
• Unlocking the Gateway: The Spatio-Temporal Dynamics of the p53 Family Driven by the Nuclear Pores and Its Implication for the Therapeutic Approach in Cancer

  2024cites this paper
• Repurposing of neprilysin inhibitor ‘sacubitrilat’ as an anti-cancer drug by modulating epigenetic and apoptotic regulators

  2023cites this paper
• Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis

  2023cites this paper
• Anti-inflammatory effects of PRIMA-1^MET (mutant p53 reactivator) induced by inhibition of nuclear factor-κB on rheumatoid arthritis fibroblast-like synoviocytes

  2022cites this paper
• Molecular pathways of apoptotic cell death

  2021cites this paper
• CX-5461 Enhances the Efficacy of APR-246 via Induction of DNA Damage and Replication Stress in Triple-Negative Breast Cancer

  2021cites this paper
• Interplay between HMGA and TP53 in cell cycle control along tumor progression

  2020cites this paper
• Cell-cycle arrest and senescence in TP53-wild type renal carcinoma by enhancer RNA-P53-bound enhancer regions 2 (p53BER2) in a p53-dependent pathway

  2020cites this paper
• p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells

  2019cites this paper
• Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53-deficient cancers to mTOR inhibition

  2019cites this paper
• Ashwagandha Bioactives for Cancer Treatment: Experimental Evidence and Their Mechanism(s) of Action

  2017cites this paper
• PRIMA-1 induces caspase-mediated apoptosis in acute promyelocytic leukemia NB4 cells by inhibition of nuclear factor-&kgr;B and downregulation of Bcl-2, XIAP, and c-Myc

  2017cites this paper
• Novel Cellular Targets of Aspirin in Chemoprevention studies on P53, G6PD and c-MYC

  2016cites this paper
• Design, Synthesis and In Vitro Activity of Anticancer Styrylquinolines. The p53 Independent Mechanism of Action

  2015cites this paper
• POLYMERIC NANOPARTICLE MEDIATED TARGETED DRUG DELIVERY TO CANCER CELLS

  2014cites this paper
• Periostin cooperates with mutant p53 to mediate invasion through the induction of STAT1 signaling in the esophageal tumor microenvironment

  2013cites this paper
• Identification of a small molecule 1,4-bis-[4-(3-phenoxy-propoxy)-but-2-ynyl]-piperazine as a novel inhibitor of the transcription factor p53

  2013cites this paper
• 以新视角观察p53家族在肺癌发生及治疗中的独特作用

  2013cites this paper
• QM-MM simulations on p53-DNA complex: a study of hot spot and rescue mutants

  2013cites this paper
• Autophagy induced by p53-reactivating molecules protects pancreatic cancer cells from apoptosis

  2012cites this paper
• TIAF1 self-aggregation in peritumor capsule formation, spontaneous activation of SMAD-responsive promoter in p53-deficient environment, and cell death

  2012cites this paper
• Mutant p53 exhibits trivial effects on mitochondrial functions which can be reactivated by ellipticine in lymphoma cells

  2011cites this paper
• The Clinical Evidence of Cellular Respiration to target Cancer By Professor

  2011cites this paper
• PRIMA-1Met/APR-246 Induces Apoptosis and Tumor Growth Delay in Small Cell Lung Cancer Expressing Mutant p53

  2011cites this paper
• Delay in Small Cell Lung Cancer Expressing Mutant p 53 / APR-246 Induces Apoptosis and Tumor GrowthMetPRIMA-1

  2011cites this paper
• Cancer Therapy : Preclinical PRIMA-1 Met / APR-246 Induces Apoptosis and Tumor Growth Delay in Small Cell Lung Cancer Expressing Mutant p 53

  2011cites this paper
• Combinatorial Approaches to Study Protein Stability: Design and Application of Cell-Based Screens to Engineer Tumor Suppressor Proteins

  2011cites this paper
• An investigation of mutant p53 function.

  2011cites this paper
• Genes de proliferación y apoptosis como factores predictivos y pronósticos en el cáncer de mama: hacia una medicina personalizada Proliferation and apoptosis genes as prognostic and predictive factors in breast cancer: towards personalized medicine

  2011cites this paper
• E6 and E7 proteins from different beta‐papillomaviruses types do not interfere in UVB‐induced apoptosis of HaCaT keratinocytes

  2011cites this paper
• APOPTOSIS: MOLECULAR MECHANISMS AND PATHOGENICITY

  2010cites this paper
• Expression and functional characterization of platelet-derived growth factor receptor-like gene.

  2010cites this paper
• p53 family members in cancer diagnosis and treatment.

  2010cites this paper
• TAR1, A Human Anti-p53 Single-Chain Antibody, Restores Tumor Suppressor Function to Mutant p53 Variants

  2010cites this paper
• Novel Perspectives on p53 Function in Neural Stem Cells and Brain Tumors

  2010cites this paper
• Protein Aggregation and Precipitation, Measurement and Control

  2010cites this paper
• Current strategies to target p53 in cancer.

  2010cites this paper
• Modulating the p53 pathway.

  2010cites this paper
• Extract from Asteraceae Brachylaena ramiflora induces apoptosis preferentially in mutant p53-expressing human tumor cells.

  2010cites this paper
• Modes of p53 Interactions with DNA in the Chromatin Context

  2010cites this paper
• Activation of Mutant Enzyme Function In Vivo by Proteasome Inhibitors and Treatments that Induce Hsp70

  2010cites this paper
• Nouvelles fonctions de p21Cip1 dans la dynamique cytosquelettique des cellules épithéliales mammaires humaines

  2010cites this paper
• Predicting Positive p53 Cancer Rescue Regions Using Most Informative Positive (MIP) Active Learning

  2009cites this paper
• Novel HIV-1 therapeutics through targeting altered host cell pathways

  2009cites this paper
• Cellular Changes and Effects of Cytokines in the Transformation of Human Mammary Epithelial Cells

  2009cites this paper
• Mutagensensitivität und DNA-Reparatur von EGFR in Schleimhautzellen von Patienten mit Plattenepithelkarzinom des oberen Aerodigestivtraktes

  2009cites this paper
• p53 Pathway Alterations in Brain Tumors

  2009cites this paper
• Implications of endoplasmic reticulum stress, the unfolded protein response and apoptosis for molecular cancer therapy. Part I: targeting p53, Mdm2, GADD153/CHOP, GRP78/BiP and heat shock proteins

  2009cites this paper
• Specifically targeted gene therapy for small-cell lung cancer

  2009cites this paper
• p53 Amino-Terminus Region (1–125) Stabilizes and Restores Heat Denatured p53 Wild Phenotype

  2009cites this paper
• Sirtuin inhibitors

  2009cites this paper
• The aflatoxin-induced TP53 mutation at codon 249 (R249S): biomarker of exposure, early detection and target for therapy.

  2009cites this paper
• PRIMA-1MET induces nucleolar translocation of Epstein-Barr virus-encoded EBNA-5 protein

  2009cites this paper
• PRIMA-1MET induces mitochondrial apoptosis through activation of caspase-2

  2008cites this paper
• p53 as a therapeutic target.

  2008cites this paper
• Apoptotic pathways in tumor progression and therapy.

  2008cites this paper
• Regression of progestin-accelerated 7,12-dimethylbenz[a]anthracene-induced mammary tumors in Sprague-Dawley rats by p53 reactivation and induction of massive apoptosis: a pilot study.

  2008cites this paper
• The transduction of His-TAT-p53 fusion protein into the human osteogenic sarcoma cell line (Saos-2) and its influence on cell cycle arrest and apoptosis

  2008cites this paper
• PRIMA-1Met induces mitochondrial apoptosis through activation of caspase-2

  2008cites this paper
• Zinc metalloproteins as medicinal targets.

  2008cites this paper
• p53 status correlates with histopathological response in patients with soft tissue sarcomas treated using isolated limb perfusion with TNF-alpha and melphalan.

  2008cites this paper
• Targeting the p53/MDM2 Pathway for Cancer Therapy

  2008cites this paper
• Mutant p53 targeting by the low molecular weight compound STIMA‐1

  2008cites this paper
• Tumor suppressor and hepatocellular carcinoma.

  2008cites this paper
• Structural biology of the tumor suppressor p53.

  2008cites this paper
• PRIMA-1MET Inhibits Growth of Mouse Tumors Carrying Mutant p53

  2008cites this paper
• Molecular pathology and potential therapeutic targets in soft-tissue sarcoma

  2008cites this paper
• BASIC SCIENCE REVIEW

  2007cites this paper
• Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants

  2007cites this paper
• Structure–function–rescue: the diverse nature of common p53 cancer mutants

  2007cites this paper
• Selective Killing of Cancer Cells by Leaf Extract of Ashwagandha: Identification of a Tumor-Inhibitory Factor and the First Molecular Insights to Its Effect

  2007cites this paper
• Cancer-derived p53 mutants suppress p53-target gene expression—potential mechanism for gain of function of mutant p53

  2007cites this paper
• Structural biology of the tumor suppressor p53 and cancer-associated mutants.

  2007cites this paper
• Structure of the human p53 core domain in the absence of DNA.

  2007cites this paper
• Reactivation of mutant p53: molecular mechanisms and therapeutic potential

  2007cites this paper
• The eIF2α Kinases PERK and PKR Activate Glycogen Synthase Kinase 3 to Promote the Proteasomal Degradation of p53*

  2007cites this paper
• Mechanisms for oncogenic activation of the epidermal growth factor receptor.

  2007cites this paper
• CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice.

  2007cites this paper
• MUTANT P53 REACTIVATION AS A NOVEL STRATEGY FOR CANCER THERAPY

  2007cites this paper
• Wild Type p53 Conformation, Structural Consequences of p53 Mutations and Mechanisms of Mutant p53 Rescue

  2007cites this paper
• P53 guardian of the genome and target for improved treatment of leukemia

  2007cites this paper
• Understanding the Effects of Cancer-Associated Mutations in the Tumor Suppressor Protein p53: Structural Consequences of Mutations and Possible Ways of Rescuing Oncogenic Mutants

  2007cites this paper
• In silico analysis of mutant p53(R249S) oncogenicity in hepatocellular carcinoma

  2007cites this paper
• Cancer-derived p 53 mutants suppress p 53-target gene expression — potential mechanism for gain of function of mutant p 53

  2007cites this paper
• Structural basis for understanding oncogenic p53 mutations and designing rescue drugs

  2006cites this paper
• Strategies for therapeutic targeting of the p53 pathway in cancer

  2006cites this paper
• Targeting the p53 tumor suppressor gene function in glioblastomas using small chemical molecules

  2006influential citation
• Functional inactivation of p53 by human T-cell leukemia virus type 1 Tax protein: mechanisms and clinical implications.

  2006cites this paper
• Expression proteomics to p53 mutation reactivation with PRIMA-1 in breast cancer cells.

  2006cites this paper
• p53 – ein natürlicher Krebskiller: Einsichten in die Struktur und Therapiekonzepte

  2006cites this paper
• p53--a natural cancer killer: structural insights and therapeutic concepts.

  2006cites this paper
• Restoring p53-mediated apoptosis in cancer cells: new opportunities for cancer therapy.

  2006cites this paper
• Effects of Common Cancer Mutations on Stability and DNA Binding of Full-length p53 Compared with Isolated Core Domains*

  2006cites this paper
• The emerging importance of DNA mapping and other comprehensive screening techniques, as tools to identify new drug targets and as a means of (cancer) therapy personalisation

  2006cites this paper
• Patented small molecule inhibitors of p53–MDM2 interaction

  2006cites this paper
• Effects of PRIMA-1 on wild-type L1210 cells expressing mutant p53 and drug-resistant L1210 cells lacking expression of p53: necrosis vs. apoptosis.

  2006cites this paper
• AWARD NUMBER: W81XWH-04-1-0723 TITLE: Proteomics Characterization of the Molecular Mechanisms of Mutant p53 Reactivation with PRIMA-1 in Breast Cancer Cells

  2006cites this paper
• Mutant human tumor suppressor p53 modulates the activation of mitogen‐activated protein kinase and nuclear factor‐κB, but not c‐Jun N‐terminal kinase and activated protein‐1

  2006cites this paper